All News
Sex differences in PsA disease expression and treatment. Treatment efficacy and retention rates lower among female PsA pts initiating first TNFi. Women presented with higher 28 TJC and PRO at baseline as well..
@RheumNow #EULAR2022 ABST#POS0077 https://t.co/yV11kCN2bZ
Robert B Chao, MD doctorRBC ( View Tweet)
#POS0709 #EULAR2022 Pooled analyses of TULIP-1 & -2 RCTs showed sustained & #lupus patients spent longer time in BICLA response vs Placebo up to 52 Wks. BILAG response was sustained in MSK, skin and constitutional domains. Be interesting to see longer follow-up data @RheumNow https://t.co/kNk7WFloLf
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Watch: EULAR Recommendations for ANCA Vasculitis
Dr. Eric Dein reviews the session held on updates to recommendations for ANCA Vasculitis, presented at the #EULAR2022 meeting in June.
https://t.co/1nr0tVIJpn https://t.co/kq0Id7PxyW
Links:
Dr. John Cush RheumNow ( View Tweet)
A Big Leap in Modulating Rheumatoid Disease
Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic.
https://t.co/QHK7c3Qhz6 https://t.co/jFR9wDCD8o
Links:
Dr. John Cush RheumNow ( View Tweet)
CTD associated ILD 🫁:
lncRNA ENST00000604692 detected in PBMCs is associated with CTD-ILD and can distinguish SSc-
ILD and RA-ILD vs. non ILD patients with AUC 0.79.
As many lncRNA, unknown if biomarker only or has a pathogenic role.
@RheumNow OP0114 #EULAR2022 https://t.co/sR4GmaMkXD
Aurelie Najm AurelieRheumo ( View Tweet)
Lung 🫁 cancer incidence and RA
44000+ RA (EIRA prospective cohort) and 216000+ matched Ctrls Swedish registries
📍56 per 100,000
📍HR 1.77 (adjusted for smoking 🚬)
📍Risk in RA + smoking 7x higher
📍Risk 2x in Sero+ vs. sero-
No data on ttmt
#EULAR2022 @RheumNow POS0061 https://t.co/c7eh3icW2c
Aurelie Najm AurelieRheumo ( View Tweet)
B-cell depletion w/ RTX ttmt is FcγR dependant & affected by FcγRs variants 🧬
FCGR3A-158V:
*encodes the allotype ⬆️ affinity for IgG1
*is associated w/ clinical and biological responses in RA and SLE.
A new way to stratify pts for anti-CD20 therapy?
@Yuz6Yusof #EULAR2022 OP0190 https://t.co/GPiaQXaF71
Aurelie Najm AurelieRheumo ( View Tweet)
Great meeting @RheumNow. He does a great job of educating Rheumatologists around the world especially through his podcast. Great discussion on the usefulness of ultrasound for Rheumatologists #EULAR2022 https://t.co/0hw7mpX8dm
Dr Qasim Akram (South Manchester Rheumatologist) DrQasimAkram ( View Tweet)
Pascual et al. Anti-TIF1gamma and cancer risk in DM and non-DM. Cancer in 60% of DM and 21% of non-DM patients with Anti-TIF1gamma https://t.co/OxKdlmDBBD
Richard Conway RichardPAConway ( View Tweet)
Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu
Richard Conway RichardPAConway ( View Tweet)
Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074
Robert B Chao, MD doctorRBC ( View Tweet)
Vadillo et al. Clinical course in IPAF (ping @leticiakawano ) . Most frequent females in 60s. Arthritis, raynauds most common features. Most NSIP. 50% PFT deterioration 16 months. UIP, baseline fibrosis, mod/high ANA titre assoc progression @RheumNow #EULAR2022 POS1427 https://t.co/qk9zK90Wuk
Richard Conway RichardPAConway ( View Tweet)
Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts.
@RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC
Robert B Chao, MD doctorRBC ( View Tweet)
Rahman et al. 2 year results on dactylitis/enthesitis from Discover-2 study guselkumab. Sustained improvements seen over time @RheumNow #EULAR2022 POS1028 https://t.co/VZhw6g4kCB
Richard Conway RichardPAConway ( View Tweet)
“I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have other options.” – Prof. I McGinnes #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6
Richard Conway RichardPAConway ( View Tweet)
Kimme Hyrich:
💉Risks of autoimmune flare is very low (3-5%)
💉Flares are mild when present after COVID-19 vaccination
Most unvaccinated patients did NOT identify as "anti-vax"... number 1 reason is concerns about their health
#EULAR2022 @RheumNow @rheum_covid https://t.co/Ogn0raifPd
Eric Dein ericdeinmd ( View Tweet)
Karpouzas et al. ORAL Surveillance analysis. MACE, VTE, infections higher in those with acute and cumulative disease activity as measured by CDAI. @RheumNow #EULAR2022 POS0519 https://t.co/CtlISf2rxr
Richard Conway RichardPAConway ( View Tweet)
#SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should be vaccinated: K Hyrich @eular_org #EULAR2022 @RheumNow session: Types if vaccine and how they work. https://t.co/Dkl8mTQpkj
Janet Pope Janetbirdope ( View Tweet)
#EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus & disease understanding. Tour de force from blood IFN signature use to Plasmablast (correlate with activity inc. in African) and Neutrophil/myeloid signatures (nephritis) @RheumNow https://t.co/tiX55ARDvC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)